Richard J. Hatchett, MD, is Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI), a partnership of public, private, philanthropic and civil organizations that will finance and co-ordinate the development of vaccines against high priority public health threats and vaccine platform technologies to respond rapidly to emerging infectious diseases with pandemic or epidemic potential.

Prior to joining CEPI, Dr. Hatchett most recently served as acting Director of the U.S. Biomedical Advanced Research and Development Authority (BARDA), after serving for five years as BARDA’s Chief Medical Officer and Deputy Director. At BARDA, Dr. Hatchett oversaw programs to develop medical countermeasures against chemical, biological, radiological and nuclear threats, pandemic influenza, and emerging infectious diseases and led or helped lead the development of vaccines, therapeutics, and diagnostics for a number of emerging viruses, including the H3N2v and H7N9 influenza viruses, MERS, Ebola, and Zika. Previously, Dr. Hatchett served on the White House Homeland Security Council under President George W. Bush and was a member of the White House National Security Staff under President Barack Obama. He is a recipient of the HHS Secretary’s Award for Distinguished Service and a five-time recipient of the NIH Director’s Merit Award.

A graduate of Vanderbilt University and the Vanderbilt University Medical School, he completed a residency in internal medicine at the New York Hospital – Cornell Medical Center and a fellowship in medical oncology at Duke University Medical Center.


리차드 해체트는 감염병혁신연합(CEPI)의 대표이다. CEPI는 공중보건 위협에 대응한 백신 개발 및 신종 감염병 신속 대응을 위한 백신 플랫폼 기술 개발을 추진하고 필요 재원을 제공하는 기관이다.

해체트 박사는 미국 생물의약품첨단연구개발국 (BARDA)의 선임의학연구관, 부국장, 국장으로 재직한바 있다. BARDA에서 해체트 박사는 화학·생물학·방사능 위협, 팬데믹 독감, 신종 감염병에 대한 치료 사업과 독감, 메르스, 에볼라, 지카 등 다수 바이러스에 대한 백신, 치료제, 진단기기의 개발을 지휘했다. 미국 보건사회복지부 장관 공로상을 1차례, 국립보건원장 공로상을 5차례 수상하였다.

해체트 박사는 밴더빌트 의과대학을 졸업했고, 뉴욕병원 코넬의학센터에서 내과 전공의로, 듀크대학교 의학센터에서 종양학 전임의로 근무했다.